Digital RESI Pitch Session

Interested in Connecting? Please contact:
Dr. Kendell Pawelec
CEO
ceo@fibrosix.com

Message the company or request a 1:1 meeting here

FibrosIX is a pre-clinical stage biotechnology start-up, developing proprietary first-in-class small-molecule therapeutics that inhibit fibrotic disease. These drugs modulate a critical signaling pathway that plays a central role in the pathogenesis of fibrotic disease. The lead drug candidate, FBX081, is being developed for the prevention of treatment-induced lung fibrosis in cancer patients, caused by chemotherapy (bleomycin) or radiation therapy.

Pitch Video